BACKGROUND AND PURPOSE: Low doses of acetyl salicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal damage. The farnesoid X receptor (FXR) is a bile acid sensor essential for maintenance of intestinal homeostasis. Here, we have investigated whether FXR is required for mucosal protection in models of gastrointestinal injury caused by ASA and NSAIDs and if FXR activation has potential in the treatment or prevention of gastrointestinal injury caused by these agents. EXPERIMENTAL APPROACH: FXR(+/+) and FXR(-/-) mice were given ASA (10 to 100 mg·kg(-1) ) or NSAIDs. Gastric and intestinal mucosal damage assessed by measuring lesion scores. FXR were activated by giving mice natural (chenodeoxycholic acid; CDCA) or synthetic (GW4064) FXR agonists. KEY RESULTS: FXR, mRNA and protein, was detected in human and mouse stomach. FXR(-/-) mice were more prone to develop severe gastric and intestinal injury in response to ASA and NSAIDs and showed a severe reduction in the gastrointestinal expression of cystathionine-γ-lyase (CSE), an enzyme required for generation of hydrogen sulphide. CSE expression was reduced by ≈50% in wild-type mice challenged with ASA. Treating wild-type mice but not FXR(-/-) mice with CDCA or GW4064 protected against gastric injury caused by ASA and NSAIDs, by a CSE-dependent and cycloxygenase- and NO-independent, mechanism. FXR activation by GW4064 rescued mice from intestinal injury caused by naproxen. CONCLUSIONS AND IMPLICATIONS: FXR was essential to maintain gastric and intestinal mucosal barriers. FXR agonists protected against gastric injury caused by ASA and NSAIDs by a CSE-mediated mechanism.
BACKGROUND AND PURPOSE: Low doses of acetyl salicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal damage. The farnesoid X receptor (FXR) is a bile acid sensor essential for maintenance of intestinal homeostasis. Here, we have investigated whether FXR is required for mucosal protection in models of gastrointestinal injury caused by ASA and NSAIDs and if FXR activation has potential in the treatment or prevention of gastrointestinal injury caused by these agents. EXPERIMENTAL APPROACH: FXR(+/+) and FXR(-/-) mice were given ASA (10 to 100 mg·kg(-1) ) or NSAIDs. Gastric and intestinal mucosal damage assessed by measuring lesion scores. FXR were activated by giving mice natural (chenodeoxycholic acid; CDCA) or synthetic (GW4064) FXR agonists. KEY RESULTS:FXR, mRNA and protein, was detected in human and mouse stomach. FXR(-/-) mice were more prone to develop severe gastric and intestinal injury in response to ASA and NSAIDs and showed a severe reduction in the gastrointestinal expression of cystathionine-γ-lyase (CSE), an enzyme required for generation of hydrogen sulphide. CSE expression was reduced by ≈50% in wild-type mice challenged with ASA. Treating wild-type mice but not FXR(-/-) mice with CDCA or GW4064 protected against gastric injury caused by ASA and NSAIDs, by a CSE-dependent and cycloxygenase- and NO-independent, mechanism. FXR activation by GW4064 rescued mice from intestinal injury caused by naproxen. CONCLUSIONS AND IMPLICATIONS: FXR was essential to maintain gastric and intestinal mucosal barriers. FXR agonists protected against gastric injury caused by ASA and NSAIDs by a CSE-mediated mechanism.
Authors: Takeshi Inagaki; Mihwa Choi; Antonio Moschetta; Li Peng; Carolyn L Cummins; Jeffrey G McDonald; Guizhen Luo; Stacey A Jones; Bryan Goodwin; James A Richardson; Robert D Gerard; Joyce J Repa; David J Mangelsdorf; Steven A Kliewer Journal: Cell Metab Date: 2005-10 Impact factor: 27.287
Authors: M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan Journal: Science Date: 1999-05-21 Impact factor: 47.728
Authors: D J Parks; S G Blanchard; R K Bledsoe; G Chandra; T G Consler; S A Kliewer; J B Stimmel; T M Willson; A M Zavacki; D D Moore; J M Lehmann Journal: Science Date: 1999-05-21 Impact factor: 47.728
Authors: Stefano Fiorucci; Elisabetta Antonelli; Eleonora Distrutti; Giovanni Rizzo; Andrea Mencarelli; Stefano Orlandi; Renata Zanardo; Barbara Renga; Moses Di Sante; Antonio Morelli; Giuseppe Cirino; John L Wallace Journal: Gastroenterology Date: 2005-10 Impact factor: 22.682
Authors: R Langenbach; S G Morham; H F Tiano; C D Loftin; B I Ghanayem; P C Chulada; J F Mahler; C A Lee; E H Goulding; K D Kluckman; H S Kim; O Smithies Journal: Cell Date: 1995-11-03 Impact factor: 41.582
Authors: Carmen Festa; Simona De Marino; Adriana Carino; Valentina Sepe; Silvia Marchianò; Sabrina Cipriani; Francesco S Di Leva; Vittorio Limongelli; Maria C Monti; Angela Capolupo; Eleonora Distrutti; Stefano Fiorucci; Angela Zampella Journal: Front Pharmacol Date: 2017-03-30 Impact factor: 5.810